Systemic inflammation increases the atherogenicity of LDL.

A comprehensive body of evidence supports the claim that systemic inflammation acts as a critical potentiator of atherosclerosis by activating the endothelium and modifying the behavior of low-density lipoprotein (LDL) within the arterial wall.

Clinical and synergistic risk

Clinical data demonstrate a powerful synergy between systemic inflammation and LDL levels. While LDL provides the lipid substrate for plaque, inflammation dictates the pace and severity of the disease.

• Synergistic Hazard: In large cohorts such as the UK Biobank and the Kailuan study, individuals with both high LDL-C and high-sensitivity C-reactive protein (hs-CRP) exhibited a significantly higher hazard ratio for major adverse cardiovascular events (HR 1.77) compared to those with elevation in only one marker.
• Residual Inflammatory Risk: Even when LDL-C is aggressively controlled (≤70 mg/dL), high residual inflammation (hs-CRP >2 mg/L) remains a potent independent predictor of cardiovascular mortality, with hazard ratios as high as 4.33 in certain populations.

Mechanistic pathways of endothelial activation

Systemic inflammation drives endothelial activation through well-defined molecular signaling cascades that impair vascular function.

• eNOS Inhibition: CRP directly binds to Fcγ receptors on endothelial cells, triggering Src kinases that inhibit endothelial nitric oxide synthase (eNOS). This reduction in nitric oxide bioavailability is a hallmark of endothelial activation.
• Adhesion Molecule Upregulation: Inflammation activates the NF-κB pathway and stimulates the production of reactive oxygen species (ROS). This leads to the increased expression of ICAM-1 and VCAM-1, which act as "molecular glue" for circulating leukocytes.

LDL retention and oxidative modification

Once the endothelium is activated, the physical and chemical environment of the arterial wall changes to favor plaque formation.

• Enhanced Retention: Activated endothelial cells show increased permeability and transcytosis. Once LDL enters the subendothelial space, it is more likely to be trapped by high-affinity interactions with proteoglycans like biglycan, which is the rate-limiting step in atherogenesis.
• Oxidative Transformation: The activated endothelium generates ROS and facilitates enzymatic oxidation via myeloperoxidase and the LOX-1 receptor. This transforms native LDL into oxidized LDL (oxLDL), which is more readily engulfed by macrophages to form foam cells, the building blocks of arterial plaque.

Bottom line

Systemic inflammation is not merely a marker of risk but a causal driver that makes LDL exposure more hazardous. By activating the endothelium, inflammation increases the time LDL spends in the arterial wall and accelerates its conversion into its most atherogenic, oxidized form.